PT-141 vs Melanotan II
PT-141 and Melanotan II are structurally related melanocortin peptides, but they are studied for notably different research profiles. Melanotan II is investigated largely for pigmentation-associated pathways, while PT-141 (derived from Melanotan II) is studied for central nervous system melanocortin signaling. Their shared origin but divergent research focus makes them a common point of comparison.
| Property | PT-141 | Melanotan II |
|---|---|---|
| Full name | Bremelanotide | Melanotan II (MT-2) |
| Relationship | Derived from Melanotan II | Parent compound |
| Primary research focus | Central melanocortin (MC4R) signaling | Pigmentation pathways |
| Mechanism (research) | MC4R agonism (CNS) | Melanocortin agonism (incl. MC1R) |
| Research angle | Neurological/behavioral | Melanogenesis |
PT-141 (Bremelanotide)
PT-141 is a melanocortin peptide derived from Melanotan II, studied for central nervous system signaling associated with MC4R rather than pigmentation. In our catalog it is listed as PT-141. See our PT-141 overview.
Melanotan II
Melanotan II is the parent melanocortin peptide, studied largely for pigmentation-associated pathways including melanogenesis. In our catalog it is listed as Melanotan II (MT-2). See our Melanotan II overview.
How Researchers Distinguish Them
Though structurally related, the two are studied for different pathways: PT-141 for central melanocortin (MC4R) signaling, Melanotan II for pigmentation. Research selecting between them depends on whether the focus is neurological/behavioral signaling or melanogenesis.
Shop these compounds
Frequently Asked Questions
Are PT-141 and Melanotan II the same?
No. PT-141 is derived from Melanotan II but is studied for a different, CNS-focused research profile.
Why compare them?
They share an origin but diverge in research focus — pigmentation versus central signaling.
Are these FDA approved?
No. Both are research compounds sold strictly for in-vitro study and not approved for human consumption.